Główne pojęcia
Factor XI inhibitors show promise in reducing bleeding risk while preventing thrombotic events.
Streszczenie
The content discusses the potential of Factor XI inhibitors as safe anticoagulants for preventing strokes and other thrombotic events. It highlights the results of the phase 2 AZALEA-TIMI 71 study, emphasizing the significant reduction in bleeding risk with the Factor XI inhibitor abelacimab compared to rivaroxaban. The role of Factor XI in the coagulation cascade and the need for safer anticoagulants are explored. The development of Factor XI inhibitors by the pharmaceutical industry and ongoing phase 3 trials are detailed, along with potential indications and differences between the leading candidates.
Statystyki
The phase 2 AZALEA-TIMI 71 study was stopped early due to an "overwhelming" reduction in major and clinically relevant nonmajor bleeding with the Factor XI inhibitor abelacimab compared to rivaroxaban.
Patients with AF currently do not take anticoagulants due to concerns about bleeding risks.
The AZALEA study was the largest and longest study of a Factor XI inhibitor to date, following 1287 patients for a median of 2 years.
Cytaty
"We are hopeful that factor XI inhibitors might be those anticoagulants." - John Alexander, MD
"We think that factor XI inhibitors may prevent the pathologic formation of thrombosis while allowing formation of thrombus for natural hemostasis to prevent bleeding. That is why they are so promising." - Manesh Patel, MD
"If these drugs are as effective at preventing strokes as DOACs, they will be a huge breakthrough, and there is good reason to think they would replace the DOACs." - John Alexander, MD